Is Wegovy Approved for Weight Loss?
Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension or type 2 diabetes, and also in children aged 12 and older with obesity.[1] Dosing starts at 0.25 mg weekly via subcutaneous injection, titrating up to 2.4 mg to minimize side effects like nausea.[1]
How Does Wegovy Work for Weight Loss?
It mimics GLP-1, a hormone that regulates appetite and slows gastric emptying, leading to reduced calorie intake and about 15-17% body weight loss in clinical trials over 68 weeks.[1][2] Unlike Ozempic (same active ingredient but lower dose), Wegovy targets weight loss primarily, while Ozempic focuses on diabetes.
Who Qualifies and What Are the Requirements?
Eligibility requires BMI ≥30 (obese) or ≥27 (overweight) with comorbidities; it's not for cosmetic use or short-term dieting.[1] Patients must combine it with a reduced-calorie diet and exercise. It's not recommended during pregnancy or breastfeeding due to potential fetal harm.[1]
Common Side Effects Patients Report
Gastrointestinal issues top the list: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in trials.[1] Serious risks include pancreatitis, gallbladder problems, thyroid tumors (in rodents), and kidney injury. Long-term use may cause muscle loss or 'Ozempic face' (facial sagging from rapid fat reduction).[2]
Wegovy vs. Alternatives Like Ozempic or Mounjaro
| Drug | Active Ingredient | Max Dose | Avg. Weight Loss | Primary Approval | Cost (Monthly, Uninsured) |
|------|-------------------|----------|------------------|------------------|---------------------------|
| Wegovy | Semaglutide | 2.4 mg | 15-17% | Weight loss | $1,300-$1,700 [3] |
| Ozempic | Semaglutide | 2.0 mg | 10-15% (off-label) | Diabetes | $900-$1,300 [3] |
| Mounjaro | Tirzepatide | 15 mg | 20-22% | Diabetes (weight loss off-label) | $1,000-$1,300 [3] |
| Zepbound | Tirzepatide | 15 mg | 20-22% | Weight loss | $1,000-$1,300 [3] |
Ozempic is often used off-label for weight loss due to shortages, but Wegovy has higher dosing for better results. Mounjaro/Zepbound may outperform on weight loss via dual GLP-1/GIP action.[2]
Off-Label Use and Legal Risks
Yes, doctors prescribe Wegovy off-label for other cases like PCOS-related weight gain, but insurance rarely covers it outside approved uses. Compounded semaglutide (cheaper generics) surged amid shortages but faces FDA scrutiny for safety and dosing errors.[2]
Cost, Coverage, and Access Issues
List price is ~$1,350/month; Novo Nordisk offers savings cards capping copays at $25 for eligible insured patients.[3] Medicare covers it for obesity since 2024, but many plans exclude weight loss drugs. Shortages persist into 2025, driving black-market risks.[2]
When Does Wegovy's Patent Expire?
Core patents on semaglutide expire in the US around 2030-2032, with formulation patents extending to 2036; Novo Nordisk faces challenges from Hims & Hers and others.[4] Biosimilars unlikely before 2032.
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[2]: NEJM Trial (STEP 1) - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3]: GoodRx Pricing Data - https://www.goodrx.com/wegovy
[4]: DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/WEGOVY